Introduction:

The main cause of early mortality in polytrauma patients is hypovolemia secondary to massive hemorrhage. Hemocomponent and crystalloid therapy is an essential and life-saving mechanism in these situations as a measure of volume replacement. In the same way, patients with severe traumatic injuries have a significant acute decrease in circulating platelet counts that makes them candidates for transfusion of platelet components; However, the use of these blood components can lead to unwanted outcomes such as increased mortality. Although many studies reveal an increase in mortality as an outcome associated with the use of blood components, others establish its use as a reducing measure of this outcome.

Objective:

to present the main indications of blood components in polytrauma patients, as well as to relate the adverse events associated with their use that influence the mortality and hospitalization time of these patients.

Devlopment:

Mortality associated with the use of blood components is still a controversial issue. In massive hemorrhage, rapid and efficient transfusion support is essential in the treatment and care of polytrauma, hence it is necessary to have transfusion protocols that improve results and reduce complications. In addition, the need for new studies on the subject to improve these protocols and reduce complications was identified.

        · resumen en Español     · texto en Español     · Español ( pdf )